{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:21:53Z","timestamp":1785918113862,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007639.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000}}],"reference-count":210,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007639.pub3","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T11:39:36Z","timestamp":1699529976000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nebuliser systems for drug delivery in cystic fibrosis"],"prefix":"10.1002","volume":"2023","author":[{"given":"Gemma","family":"Stanford","sequence":"additional","affiliation":[{"name":"Department of Adult Cystic Fibrosis; Royal Brompton Hospital, Guys and St Thomas's NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Morrison","sequence":"additional","affiliation":[{"name":"West of Scotland Adult CF Unit; Queen Elizabeth University Hospital (The Southern General Hospital); Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Brown","sequence":"additional","affiliation":[{"name":"West Midlands Adult Cystic Fibrosis Centre; Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"issue":"Suppl 1","key":"10.1002\/14651858.CD007639.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S1569-1993(06)80156-6","article-title":"Reduction of drug-dose and therapy-costs in the inhalation therapy with high dose tobramycin","volume":"5","author":"Brand","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"issue":"8","key":"10.1002\/14651858.CD007639.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/adc.88.8.715","article-title":"Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis","volume":"88","author":"Byrne","year":"2003","journal-title":"Archives of Disease in Childhood"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0003|cit3","unstructured":"Spencer DA Byrne N Keavey PM Snowdon V Hawkins T Radionuclide assessment of lung deposition of nebulised antibiotics in patients with cystic fibrosis 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 P75"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0004|cit4","first-page":"314","article-title":"Radionuclide assessment of lung deposition of nebulised antibiotics in patients with cystic fibrosis","volume":"32 (Suppl 22)","author":"Spencer","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0005|cit5","unstructured":"Spencer DA Byrne N Perry J Gould K Microbiological assessment of antibiotic delivery using two nebuliser systems in patients with cystic fibrosis 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 P219"},{"issue":"2","key":"10.1002\/14651858.CD007639.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jcf.2006.06.002","article-title":"Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis","volume":"6","author":"Clavel","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD007639.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ppul.21376","article-title":"Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis","volume":"46","author":"Coates","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S66, Abstract n","DOI":"10.1016\/S1569-1993(09)60261-7","article-title":"Lung delivery of a new tobramycin nebuliser solution (150mg\/1.5ml) by an investigational eFlow\u00ae nebuliser is equivalent to TOBI\u00ae but in a fraction of time","volume":"8 (Suppl 2)","author":"Denk","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S22, Abstract n","DOI":"10.1016\/S1569-1993(10)60085-9","article-title":"In-vivo data support equivalent therapeutic efficacay of a new tobramycin inhalation solution (150mg\/1.5ml) administered by the eFlow\u00ae electronic nebuliser compared to TOBI\u00ae in the PARI LC PLUS\u00ae","volume":"9 (Suppl 1)","author":"Keller","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"10.1002\/14651858.CD007639.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1183\/09031936.97.10112479","article-title":"Comparison of drug delivery from conventional versus \"venturi\" nebulisers","volume":"10","author":"Devadason","year":"1997","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0011|cit11","unstructured":"Devadason SG Huang T Walker SL Troedson R Le Souef PN Lung deposition of rhDNase in children with cystic fibrosis using the Halolite adaptive aerosol delivery (AAD) systems and Pari LC+ nebulizer 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 P84"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0012|cit12","first-page":"S67:P161","article-title":"Comparison of compliance in Cystic Fibrosis patients using either a Halolite adaptive aerosol delivery (AAD) system of a conventional high output nebuliser system","volume":"1 (Suppl 1)","author":"Conway","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0013|cit13","first-page":"S106","article-title":"Interaction between bronchodilators and nebuliser device in Cystic Fibrosis patients taking Colistin using a halolite adaptive aerosol delivery (AAD) system compared to a high output conventional nebuliser system","volume":"1 (Suppl 1)","author":"Dodd","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0014|cit14","first-page":"321","article-title":"Interaction between aerosol delivery system and bronchodilators in CF patients taking colistin","volume":"34 (Suppl 24)","author":"Dodd","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0015|cit15","first-page":"iii39","article-title":"Interaction between aerosol delivery system and bronchodilators in CF patients taking colistin","volume":"57 (Suppl 3)","author":"Dodd","year":"2002","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0016|cit16","first-page":"S105","article-title":"A multi-centre, randomised study comparing the halolite adaptive aerosol delivery system with a high output nebuliser system in patients with cystic fibrosis","volume":"1 (Suppl 1)","author":"Marsden","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0017|cit17","first-page":"320","article-title":"Comparison of the halolite adaptive aerosol delivery (AAD) system with a high output nebuliser system in CF patients","volume":"34 (Suppl 24)","author":"Marsden","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0018|cit18","first-page":"iii80","article-title":"Comparison of the halolite adaptive aerosol system with a high output nebuliser system in cystic fibrosis patients","volume":"57 (Suppl 3)","author":"Marsden","year":"2002","journal-title":"Thorax"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD007639.pub3-BIB0019|cit19","first-page":"141","article-title":"Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods","volume":"58","author":"Dopfer","year":"2007","journal-title":"Journal of Physiology and Pharmacology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0020|cit20","unstructured":"Haeussermann S Dopfer R Brand P Muellinger B Meyer TH Scheuch G Tobramycin serum concentrations after conventional and controlled inhalations in patients with cystic fibrosis American Thoracic Society International Conference; 2006 May 19-24; California, USA 2006 A407"},{"issue":"4","key":"10.1002\/14651858.CD007639.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1378\/chest.111.4.955","article-title":"A comparison of peak sputum concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems","volume":"111","author":"Eisenberg","year":"1997","journal-title":"Chest"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1569-1993(06)80164-5","article-title":"Comparison of Pari LC-Star and -Plus nebulisers delivering 2.5mg recombinant human deoxyribonuclease (rhDNase)","volume":"5 (Suppl 1)","author":"Elkins","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1378\/chest.108.1.153","article-title":"Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase I to patients with cystic fibrosis","volume":"108","author":"Fiel","year":"1995","journal-title":"Chest"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/(SICI)1099-0496(199708)24:2<155::AID-PPUL16>3.0.CO;2-1","article-title":"Aerosolized dornase alpha in cystic fibrosis: is there a role in the management of patients with early obstructive lung disease?","volume":"24 (Suppl 2)","author":"Geller","year":"1997","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0025|cit25","first-page":"S35","article-title":"Aerosolized dornase alpha in cystic fibrosis: smaller particle size may improve outcome in patients with mild obstructive lung disease","volume":"32 Suppl","author":"Geller","year":"1996","journal-title":"Israel Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/(SICI)1099-0496(199802)25:2<83::AID-PPUL2>3.0.CO;2-O","article-title":"Effect of smaller droplet size of dornase alpha on lung function in mild cystic fibrosis","volume":"25 (Suppl 2)","author":"Geller","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1378\/chest.123.1.28","article-title":"Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system","volume":"123","author":"Geller","year":"2003","journal-title":"Chest"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0028|cit28","first-page":"292","article-title":"Aerodose improves TOBI delivery in cystic fibrosis","volume":"32 (Suppl 22)","author":"Wilmott","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pupt.2012.12.002","article-title":"Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution300 mg\/4 ml administered by PARI eFlow\u00ae rapid and PARI LC Plus\u00ae nebulisersin cystic fibrosis patients","volume":"26","year":"2013","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD007639.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pupt.2012.12.002","article-title":"Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg\/4 ml administered by PARI eFlow((R)) rapid and PARI LC Plus((R)) nebulisers in cystic fibrosis patients","volume":"26","author":"Govoni","year":"2013","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0031|cit31","first-page":"606s","article-title":"Pharmacokinetics of tobramycin nebulizer solution (300mg\/4ml) administered by Pari e-Flow rapid vs Pari LC plus nebulizer in patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"40 (Suppl 56)","author":"Govoni","year":"2012","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"S129, Abstract","DOI":"10.1016\/S1569-1993(12)60453-6","article-title":"Pharmacokinetics of tobramycin nebulizer solution (Bramitob\u00ae) administered by Pari e-Flow Rapid vs Pari LC Plus nebulizer in patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"10 (Suppl 1)","author":"Govoni","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0033|cit33","unstructured":"Pharmacokinetic study of bramitob\u00ae administered for inhalation by PARI eFlow\u00ae vs PARI LC\u00ae PLUS nebulizer clinicaltrials.gov\/ct2\/show\/NCT01116089"},{"issue":"3","key":"10.1002\/14651858.CD007639.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/jamp.2012.1022","article-title":"A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI","volume":"27","author":"Griese","year":"2014","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0035|cit35","first-page":"300, Abstract n","article-title":"Pulmonary delivery of tobramycin by an investigational Eflow\u00ae electronic nebulizer saves 50% of the drug, and results in equivalent or improved tobramycin safety levels in plasma and sputum","volume":"44 (Suppl 32)","author":"Griese","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD007639.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/jamp.2014.1173","article-title":"Lung deposition of alpha-proteinase inhibitor (human) (A-PI[H]) inhalation solution using two inhalation modes of the I-neb adaptive aerosol delivery (AAD) system in healthy subjects and subjects with cystic fibrosis","volume":"29","author":"Haussermann","year":"2016","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S1569-1993(07)60043-5","article-title":"Pharmacokinetic comparison of inhaled tobramycin (TOBI) via Pari eFlow rapid or Pari LC Plus nebulizers in cystic fibrosis","volume":"6 (Suppl 1)","author":"Hubert","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD007639.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jcf.2009.07.001","article-title":"Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis","volume":"8","author":"Hubert","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0039|cit39","first-page":"289","article-title":"Tobramycin inhalation solution (TOBI) administered via Pari Eflow Rapid nebuliser may yield a higher therapeutic ratio vs Pari LC Plus jet nebuliser in cystic fibrosis patients","volume":"42 (Suppl 30)","author":"Tavakkol","year":"2007","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0040|cit40","first-page":"A77","article-title":"Comparitive assessment of aerosol delivery in cystic fibrosis","volume":"55 (Suppl 3)","author":"Kastelik","year":"2000","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0041|cit41","first-page":"247","article-title":"Radiolabelled DTPA as a tool to study nebuliser performance: a comparison of two systems in cystic fibrosis and healthy volunteers","volume":"30 (Suppl 20)","author":"Kastelik","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0042|cit42","first-page":"247","article-title":"Radiolabelled DTPA as a tool to study nebuliser performance: a comparison of two systems in cystic fibrosis and healthy volunteers","volume":"Suppl 20","author":"Kastelik","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1006\/pupt.2002.0391","article-title":"A widely available method for the assessment of aerosol delivery in cystic fibrosis","volume":"15","author":"Kastelik","year":"2002","journal-title":"Pulmonology Pharmacology & Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1006\/pupt.2002.0391","article-title":"A widely available method for the assessment of aerosol delivery in cystic fibrosis","volume":"15","author":"Kastelik","year":"2002","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0045|cit45","unstructured":"K\u00f6hler E Sollich V Schuster R Lung deposition in CF patients using ultrasonic or jet nebulising XIIIth International Cystic Fibrosis Conference; 2000 4-8 June, Stockholm, Sweden 2000 144"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0046|cit46","first-page":"S65","article-title":"Lung deposition following electronically breath controlled inhalation and manually triggered conventional inhalation in CF patients","volume":"3 (Suppl 1)","author":"K\u00f6hler","year":"2004","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/089426803764928347","article-title":"Lung deposition in cystic fibrosis patients using an ultrasonic or a jet nebuliser","volume":"16","author":"K\u00f6hler","year":"2003","journal-title":"Journal of Aerosol Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jcf.2010.08.019","article-title":"Lung deposition of inhaled tobramycin with eFlow rapid\/LC plus jet nebuliser in healthy and cystic fibrosis subjects","volume":"10","author":"Lenney","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0049|cit49","first-page":"726","article-title":"Comparison of therapeutic nebuliser performance in cystic fibrosis using Tc-99m DTPA aerosol","volume":"22","author":"Marshall","year":"1992","journal-title":"Australian and New Zealand Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1440-1754.1994.tb00569.x","article-title":"Aerosol deposition in cystic fibrosis using an aerosol conservation device and a conventional jet nebuliser","volume":"30","author":"Marshall","year":"1994","journal-title":"Journal of Paediatrics and Child Health"},{"issue":"5","key":"10.1002\/14651858.CD007639.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jcf.2011.04.006","article-title":"A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis","volume":"10","author":"McCormack","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"S54, Abstract n","DOI":"10.1016\/S1569-1993(11)60230-0","article-title":"Open-label study: a comparison of breathing modes for adaptive aerosol delivery in children with cystic fibrosis","volume":"10 (Suppl 1)","author":"McCormack","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/jamp.2011.0934","article-title":"New nebulizer technology to monitor adherence and nebulizer performance in Cystic Fibrosis","volume":"25","author":"McCormack","year":"2012","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0054|cit54","unstructured":"Tobramycin inhalation solution administered by eFlow rapid nebulizer: scintigraphy study clinicaltrials.gov\/ct2\/show\/NCT00399945"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0055|cit55","unstructured":"CTBM100B 2202 - study results www.novctrd.com\/#\/product?type=clinicalM&medicalConditionId=126&productId=320"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0056|cit56","unstructured":"CTBM100B2201 www.novctrd.com\/#\/product?type=clinicalM&medicalConditionId=126&productId=320"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0057|cit57","unstructured":"Tobramycin administered by eFlow rapid nebulizer: pharmacokinetic study clinicaltrials.gov\/ct2\/show\/NCT00420836"},{"issue":"4","key":"10.1002\/14651858.CD007639.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/thx.43.4.318","article-title":"Deposition of carbenicillin aerosols in cystic fibrosis: effects of nebuliser system and breathing pattern","volume":"43","author":"Newman","year":"1988","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jcf.2014.04.006","article-title":"Comparison of two tobramycin nebuliser solutions: Pharmokinetic, efficacy and safety profiles of T100 and TNS","volume":"13","author":"Sands","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0060|cit60","first-page":"S66, Abstract n","article-title":"A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection for pharmacokinetic and therapeutic equivalence","volume":"12 (Suppl 1)","author":"Sands","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0061|cit61","first-page":"P1188, Abstract","article-title":"Use of an electronic monitoring system to generate objective information on patients' adherence to taking treatments of a novel inhaled tobramycin solution","volume":"42","author":"Sands","year":"2013","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0062|cit62","first-page":"S66, Abstract n","article-title":"Use of an electronic monitoring system to generate objective information on patients' adherence to taking treatments of a novel tobramycin solution (VANTOBRA)","volume":"12 (Suppl 1)","author":"Sands","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0063|cit63","first-page":"452, Abstract n","article-title":"A study to evaluate the comparable efficacy and safety of Pulmozyme\u00ae delivered by the Erapid\u2122 nebulizer system","volume":"48 (Suppl 36)","author":"Konstan","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0064|cit64","unstructured":"A study of the comparable efficacy and safety of pulmozyme (dornase alfa) delivered by the erapid nebulizer system in patients with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT01712334"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2015.04.003","article-title":"Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients","volume":"14","author":"Sawicki","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0066|cit66","first-page":"445","article-title":"Impact of dornase alfa delivered by the eRapid\u2122 vs. Pari LC\u00ae plus jet nebulizer system on cystic fibrosis-related quality of life - results from the IMPART Study","volume":"49 (Suppl 38)","author":"Sawicki","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0067|cit67","first-page":"444, Abstract n","article-title":"Treatment preferences and satisfaction with dornase alfa delivered by the eRapid\u2122 vs. Pari LC\u00ae plus jet nebulizer system to patients with cystic fibrosis - results from the IMPART Study","volume":"49 (Suppl 38)","author":"Sawicki","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0068|cit68","first-page":"S222","article-title":"An evaluation of two aerosol delivery systems for rhDNase [abstract]","volume":"32 Suppl","author":"Shah","year":"1996","journal-title":"Israel Journal of Medical Sciences"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1183\/09031936.97.10061261","article-title":"An evaluation of two aerosol delivery systems for rhDNase","volume":"10","author":"Shah","year":"1997","journal-title":"European Respiratory Journal"},{"issue":"10","key":"10.1002\/14651858.CD007639.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/thx.46.10.717","article-title":"Pulmonary deposition of nebulised amiloride in cystic fibrosis:comparison of two nebulisers","volume":"46","author":"Thomas","year":"1991","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007639.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1016\/S1569-1993(13)60338-0","article-title":"Influence of inhalation mode on aerosol lung deposition in patients with cystic fibrosis PART 1: pharmacokinetic data as representative of lung deposition","volume":"12","author":"Velzen","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jcf.2015.01.002","article-title":"The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis","volume":"14","author":"Velzen","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007639.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S1569-1993(14)60092-8","article-title":"Influence of breathing pattern on pulmonary aerosol deposition in patients with cystic fibrosis (CF): a pharmacokinetic approach","volume":"13","author":"Velzen","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0074|cit74","first-page":"326","article-title":"Pharmacokinetics and tolerability in cystic fibrosis of double dose nebulized tobramycin using controlled and conventional inhalation","volume":"50 Suppl 41","author":"Bos","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0075|cit75","unstructured":"Targeting antibiotics to Pseudomonas aeruginosa in small airways (TAPAS) study in patients with cystic fibrosis: pharmacokinetics (PK) trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2013-004488-30-NL"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0076|cit76","unstructured":"Once daily deep inhalation of tobramycin with smart nebulizer more effective to treat small airways disease in cystic fibrosis? trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2014-001401-41-NL"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0077|cit77","unstructured":"Targeting antibiotics to pseudomonas aeruginosa in small airways (TAPAS) study in patients with cystic fibrosis: pharmacokinetics (PK) trialsearch.who.int\/Trial2.aspx?TrialID=NTR4525"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0078|cit78","unstructured":"TAPAS study in patients with CF trialsearch.who.int\/Trial2.aspx?TrialID=NTR5211"},{"issue":"15","key":"10.1002\/14651858.CD007639.pub3-BIB0079|cit79","first-page":"25","article-title":"Pharmacokinetics and tolerability of once daily double dose tobramycin inhalation in cystic fibrosis using controlled and conventional nebulization: comparison between PARI-LC Plus and AKITA nebulizer","volume":"154","author":"Van Velzen","journal-title":"Pharmaceutisch Weekblad"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"S26, Abstract n","DOI":"10.1016\/S1569-1993(15)30083-7","article-title":"Pharmacokinetics and safety of once daily double dose inhaled tobramycin administered with the controlled-inhalation AKITA\u00ae and conventional PARI-LC\u00ae Plus nebulizer in cystic fibrosis","volume":"14 (Suppl 1)","author":"Velzen","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD007639.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/jamp.2015.1259","article-title":"Pharmacokinetics and tolerability of once daily double dose tobramycin inhalation in cystic fibrosis using controlled and conventional nebulization","volume":"29","author":"Velzen","year":"2016","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0082|cit82","unstructured":"Tobramycin nebulisation with I-neb (TONI) study in children with cystic fibrosis: pharmacokinetics and safety trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2012-002503-17-NL"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0083|cit83","unstructured":"Tobramycin nebulisation with I-neb (TONI) study in children with cystic fibrosis: pharmacokinetics and safety trialsearch.who.int\/Trial2.aspx?TrialID=NTR4216"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"S49, Abstract n","DOI":"10.1016\/S1569-1993(15)30158-2","article-title":"Tobramycin nebulization with I-neb\u00aein children with cystic fibrosis (TONI study): pharmacokinetics and safety","volume":"14 (Suppl 1)","author":"Velzen","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"9","key":"10.1002\/14651858.CD007639.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/bcp.13988","article-title":"Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: a randomized, crossover study","volume":"85","author":"Velzen","year":"2019","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1569-1993(17)30239-4","article-title":"Tobramycin nebulization with the I-neb\u00aein children with cystic fibrosis (TONI study): pharmacokinetics and safety","volume":"16 (Suppl 1)","author":"Velzen","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD007639.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/jamp.2007.0674","article-title":"Aerosolization of tobramycin (TOBI) with the PARI LC plus reusable nebulizer: which compressor to use? Comparison of the CR60 to the portaneb compressor","volume":"21","author":"Westerman","year":"2008","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1569-1993(07)60147-7","article-title":"Portaneb or CR60? Inhalation of tobramycin (TOBI) with the Pari LC Plus nebuliser: an in-vivo pilot study","volume":"6 (Suppl 1)","author":"Westerman","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"695","DOI":"10.18093\/0869-0189-2019-29-6-695-706","article-title":"Efficacy and safety of the biosimilar medicinal product Tigerase\u00ae (dornase alfa) in long-term symptomatic treatment of patients with cystic fibrosis: results of a phase III clinical trial","volume":"29","author":"Amelina","year":"2019","journal-title":"Pulmonologiya"},{"issue":"12","key":"10.1002\/14651858.CD007639.pub3-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"e0261410","DOI":"10.1371\/journal.pone.0261410","article-title":"Comparison of biosimilar Tigerase and Pulmozyme in long-term symptomatic therapy of patients with cystic fibrosis and severe pulmonary impairment (subgroup analysis of a Phase III randomized open-label clinical trial (NCT04468100))","volume":"16","author":"Amelina","year":"2021","journal-title":"PLOS One"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007639.pub3-BIB0091|cit91","first-page":"S65","article-title":"A pilot study to investigate the lung deposition of aerosol nebulised solutions using two different nebuliser systems in to the lungs of cystic fibrosis (CF) patients","volume":"3","author":"Coldham","year":"2004","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0092|cit92","first-page":"175","article-title":"Sputum gentamicin (G) levels after delivery by rotahaler and nebuliser","volume":"16 (Suppl 9)","author":"Conway","year":"1993","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0093|cit93","unstructured":"Watson A Pond M Bayston S Booth R Chonheim A Conway SP Sputum gentamicin (G) levels after delivery by rotahaler and nebuliser 18th European Cystic Fibrosis Conference; 1993 May 21-26; Madrid, Spain 1993 W2.1"},{"issue":"5","key":"10.1002\/14651858.CD007639.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1164\/ajrccm.160.5.9810080","article-title":"Dry powder versus intravenous and nebulized gentamycin in cystic fibrosis and bronchiectasis. A pilot study","volume":"160","author":"Crowther Labris","year":"1999","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"S74, Abstract n","DOI":"10.1016\/S1569-1993(09)60293-9","article-title":"A randomised, cross-over trial of upright sitting versus alternate side lying during nebulised delivery of medication in cystic fibrosis","volume":"8 (Suppl 2)","author":"Dentice","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0096|cit96","first-page":"369, Abstract n","article-title":"Does inhalation in side lying influence the delivery rate of nebulised medications in people with cystic fibrosis?","volume":"44 (Suppl 32)","author":"Dentice","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0097|cit97","first-page":"S74, Abstract n","article-title":"Does body position during inhalation of a nebulised aerosol influence the pattern of deposition in adults with and without cystic fibrosis","volume":"9 Suppl 1","author":"Dentice","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12890-017-0568-2","article-title":"The use of an alternate side lying positioning strategy during inhalation therapy does not prolong nebulisation time in adults with cystic fibrosis: a randomised crossover trial","volume":"18","author":"Dentice","year":"2018","journal-title":"BMC Pulmonary Medicine"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12890-019-0886-7","article-title":"Side lying during nebulisation can significantly improve apical deposition in healthy adults and adults with mild cystic fibrosis lung disease: a randomised crossover trial","volume":"19","author":"Dentice","year":"2019","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0100|cit100","unstructured":"Dolovich M Eng P Rhem R Guo X Labris R Thabane L Does particle size influence distribution of inhaled therapy in the presence of airways obstruction: a 3D PET study of the lung in cystic fibrosis American Thoracic Society International Conference; 2005 May 20-25, San Diego, USA 2005 A377"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0101|cit101","first-page":"368","article-title":"Pulmonary aerosol deposition in children with cystic fibrosis following transnasal delivery of hypertonic saline","volume":"51 (Suppl 45)","author":"Donn","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0102|cit102","unstructured":"Randomized, open labeled, multi center, active controlled, parallel 28 days safety and bioavailability study of Tobramycin 100 PARI nebulized with eFlow\u00ae versus TOBI\u00ae nebulized with PARI LC PLUS in cystic fibrosis patients with Pseudomonas Aeruginosa infections trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-004103-10-DE"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0103|cit103","unstructured":"Randomized, open labelled, cross over deposition study of Tobramycin 100 PARI nebulized with eFlow\u00ae versus TOBI\u00ae nebulized with PARI LC PLUS\u00ae in subjects with CF trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-000959-33-DE"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0104|cit104","unstructured":"Does nebulised tobramycin (TOBI) via e-flow delivery systems cause a raised peak serum tobramycin level in children with Cystic Fibrosis? - TOBICF trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-005346-20-GB"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0105|cit105","unstructured":"Etude pharmacocinetique de l\u2019equivalence de la biodisponibilite entre Nebcinal\u00ae 150mg\/3ml administre par Aeroneb\u00ae Idehaler\u00ae et Tobi\u00ae 300mg\/5ml administre par Pari LC Plus \u00ae trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-013660-39-FR"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0106|cit106","unstructured":"A comparative, randomised, two period, multi-center, cross-over 14 weeks bioequivalence study of Tobramycin PARI (T100) versus TOBI\u00c2\u00ae (Novartis) in cystic fibrosis patients with bronchopulmonary chronic Pseudomonas aeruginosa infection - T-100 BE trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2010-023235-41-PL"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0107|cit107","unstructured":"Etude pharmacocinetique de l\u2019equivalence de la biodisponibilite entre Nebcinal\u00ae 150mg\/3ml administre par Aeroneb\u00ae Idehaler\u00ae et Tobi\u00ae 300mg\/5ml administre par Pari LC Plus \u00ae \/Pulmoaid \u00ae chez des patients atteints de mucoviscidose trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2010-023533-34-FR"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0108|cit108","first-page":"S15, Abstract n","article-title":"Use of the AKITA JET for inhalation treatment in cystic fibrosis - part I: clinical outcomes","volume":"14 (Suppl 1)","author":"Eyns","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0109|cit109","first-page":"S15, Abstract n","article-title":"Use of the AKITA JET for inhalation treatment in cystic fibrosis - part II: patients' satisfaction","volume":"14 (Suppl 1)","author":"Eyns","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1164\/ajrccm.162.6.2003069","article-title":"Optimization of aerosol deposition by pressure support in children with cystic fibrosis: an experimental and clinical study","volume":"162","author":"Fauroux","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.mnm.0000126508.96340.1d","article-title":"Quantitative lung perfusion scan as a predictor of aerosol distribution heterogeneity and disease severity in children with cystic fibrosis","volume":"25","author":"Itti","year":"2004","journal-title":"Nuclear Medicine Communications"},{"issue":"17","key":"10.1002\/14651858.CD007639.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1753465817710596","article-title":"Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection","volume":"11","author":"Greenwood","year":"2017","journal-title":"Therapeutic Advances in Respiratory Disease"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0113|cit113","first-page":"315","article-title":"Microbial contamination profile of tobi podhaler\u2122 versus nebulizers used in cystic fibrosis patients with chronic pseudomonas aeruginosa infection: a real-world study","volume":"51 (Suppl)","author":"Greenwood","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0114|cit114","unstructured":"Hung JC Spring M Hambleton G Super M A preliminary study on the delivery of gentamycin dry powder to the lung of children with cystic fibrosis 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium 1995 P53"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/S1569-1993(22)00556-2","article-title":"\u201cCF Hero\u201d application as a motivational and therapeutic tool for kids and teenagers with cystic fibrosis","volume":"21 Suppl 1","author":"Jirasek","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0116|cit116","unstructured":"Johnson JC Waldrep JC Dhand R Aerosol delivery of recombinant human DNase 1. Comparison of a vibrating mesh nebulizer with a jet nebulizer American Thoracic Society International Conference; 2006 May 19-24; California, USA 2006 A82"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0117|cit117","unstructured":"Kovaleva LF Gembitskaya TE Zaremba IA The optimization of the therapy in cystic fibrosis (CF) patients using nebuliser 24th European Cystic Fibrosis Conference; 2001 June 6- 9; Vienna, Austria 2001 P86"},{"issue":"4","key":"10.1002\/14651858.CD007639.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1378\/chest.118.4.1069","article-title":"Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate","volume":"118","author":"Laube","year":"2000","journal-title":"Chest"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0119|cit119","first-page":"P55","article-title":"Optimal delivery of cystic fibrosis (CF) therapy from commonly recommended nebulisers","volume":"16 (Suppl 1)","author":"Liew","year":"2011","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2147\/PPA.S353434","article-title":"Objective nebuliser adherence data AS \"proof\" of adherence in the management of cystic fibrosis: a qualitative interview study","volume":"16","author":"Lumley","year":"2022","journal-title":"Patient Preference and Adherence"},{"issue":"5","key":"10.1002\/14651858.CD007639.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/(SICI)1099-0496(199605)21:5<276::AID-PPUL2>3.0.CO;2-L","article-title":"Aerosol deposition in infants with cystic fibrosis","volume":"21","author":"Mallol","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD007639.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/jam.1997.10.331","article-title":"Nebulized gentamicin in children with cystic fibrosis: Enhancing antibiotic lung deposition by increasing flow rate and fill volume","volume":"10","author":"Mallol","year":"1997","journal-title":"Journal of Aerosol Medicine"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S1569-1993(08)60256-8","article-title":"e-Flow rapid\u00ae: improved lung function and patient satisfaction with more volume delivered to the lungs during inhalation therapy in cystic fibrosis","volume":"7 (Suppl 2)","author":"Militz","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD007639.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ppul.20152","article-title":"Randomised, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease","volume":"39","author":"Moss","year":"2005","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0125|cit125","unstructured":"Mulrennan SA Moon TM Prodose nebuliser usage compared with usual nebuliser in cystic fibrosis patients American Thoracic Society International Conference; 2004 May 21- 26; Florida, USA 2004 A391"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0126|cit126","unstructured":"Pharmacokinetic bioequivalence study of nebcinal\u00ae 150mg\/3ml administered by aeroneb\u00ae idehaler\u00ae versus tobi\u00ae 300mg\/5ml administered by pari LC plus\u00ae clinicaltrials.gov\/ct2\/show\/NCT01288170"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0127|cit127","unstructured":"Pharmacokinetic bioequivalence study of nebcinal\u00ae 150mg\/3ml administered by aeroneb\u00ae idehaler\u00ae versus tobi\u00ae 300 mg\/5 ml administered by pari LC plus\u00ae \/pulmoaid\u00ae in patients with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT01337219"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0128|cit128","unstructured":"Comparison of amikacin lung delivery with two nebulizers clinicaltrials.gov\/ct2\/show\/NCT02538588"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0129|cit129","unstructured":"Podolec Z Pneumodosimeter - the application of BCTS method (bronchial control treatment systems) to breath-controlled application of medicine aerosols in water solutions to persons suffering from mucoviscidosis 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 P98"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0130|cit130","first-page":"361","article-title":"Comparison of the delivery characteristics of dornase alpha from the I-Neb AAD system and the sidestream et nebulizer","volume":"43 (Suppl 31)","author":"Potter","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 58","key":"10.1002\/14651858.CD007639.pub3-BIB0131|cit131","first-page":"1975","article-title":"Lung deposition of inhaled colistimethate sodium in cystic fibrosis patients","volume":"44","author":"Su","year":"2014","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0132|cit132","unstructured":"Coaching and telemonitoring in patients with cystic fibrosis: connect CF trialsearch.who.int\/?TrialID=DRKS00024642"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12890-021-01500-y","article-title":"A multi-centre, randomized, controlled trial on coaching and telemonitoring in patients with cystic fibrosis: conneCT CF","volume":"21","author":"Thee","year":"2021","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1569-1993(11)60259-2","article-title":"Influence of inhaled hypertonic saline (NaCl 6%) before or during autogenic drainage on sputum weight, oxygen saturation, heart frequency and dyspnea in cystic fibrosis patients","volume":"10 (Suppl 1)","author":"Van Ginderdeuren","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S1569-1993(08)60271-4","article-title":"Influence of inhaled hypertonic saline combined with airway clearance on SpO2, heart rate, dyspnoea and wet sputum weight in hospitalised CF patients","volume":"7 (Suppl 2)","author":"Vanlaethem","year":"2008","journal-title":"Journal of Cystic fibrosis"},{"issue":"10","key":"10.1002\/14651858.CD007639.pub3-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1080\/09593985.2020.1858465","article-title":"Development of a device to measure adherence and pressure characteristics of positive expiratory pressure therapies used by adults with cystic fibrosis","volume":"38","author":"Ward","year":"2022","journal-title":"Physiotherapy Theory and Practice"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0137|cit137","first-page":"382","article-title":"Expiratory duration and pressure properties of commonly used airway clearance devices when used unsupervised by adults with cystic fibrosis","volume":"54 (Suppl 2)","author":"Ward","year":"2019","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD007639.pub3-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/bjhp.12357","article-title":"Adherence to medication in adults with Cystic Fibrosis: an investigation using objective adherence data and the Theoretical Domains Framework","volume":"24","author":"Arden","year":"2019","journal-title":"British Journal of Health Psychology"},{"issue":"Suppl","key":"10.1002\/14651858.CD007639.pub3-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/S1569-1993(16)30151-5","article-title":"ACtiF study: understanding adherence to nebuliser treatment in adults with cystic fibrosis using the Theoretical Domains Framework","volume":"15 Suppl","author":"Arden","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S1569-1993(17)30358-2","article-title":"CFHealthHub: understanding psychosocial differences between high, medium and low adherers to nebuliser treatment: an exploratory analysis of data from CFHealthHub two centre pilot trial","volume":"16 (Suppl 1)","author":"Arden","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40814-020-00739-2","article-title":"Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: cFHealthHub","volume":"7","author":"Arden","year":"2021","journal-title":"Pilot and Feasibility Studies"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/S1569-1993(22)00558-6","article-title":"The introduction of an adherence support clinic in a large UK adult cystic fibrosis centre","volume":"21","author":"Choyce","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007639.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S1569-1993(22)00205-3","article-title":"Using the CFHealthHub digital learning health system to optimise the nebulised medicines supply process in 5 UK adult cystic fibrosis (CF) centres","volume":"21","author":"Dawson","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"14","key":"10.1002\/14651858.CD007639.pub3-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1177\/1049732319856580","article-title":"When is forgetting not forgetting? A discursive analysis of differences in forgetting talk between adults with cystic fibrosis with different levels of adherence to nebulizer treatments","volume":"29","author":"Drabble","year":"2019","journal-title":"Qualitative Health Research"},{"issue":"10","key":"10.1002\/14651858.CD007639.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"e16782","DOI":"10.2196\/16782","article-title":"Mechanisms of action of a web-based intervention with health professional support to increase adherence to nebulizer treatments in adults with cystic fibrosis: qualitative interview study","volume":"22","author":"Drabble","year":"2020","journal-title":"Journal of Medical Internet Research"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0146|cit146","unstructured":"Drummond D Whelan P Sperrin M Association between nebuliser therapies adherence and visit-to-visit variability of FEV1 in patients with cystic fibrosis Journal of Cystic Fibrosis S1569 1993(23)00070-X 10.1016\/j.jcf.2023.03.006"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12913-019-4260-5","article-title":"Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Health Services Research"},{"issue":"10","key":"10.1002\/14651858.CD007639.pub3-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"e039089","DOI":"10.1136\/bmjopen-2020-039089","article-title":"Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation","volume":"10","author":"Hind","year":"2020","journal-title":"BMJ open"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12890-019-0834-6","article-title":"Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study","volume":"19","author":"Hind","year":"2019","journal-title":"BMC Pulmonary Medicine"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"S40, Abstract n","DOI":"10.1016\/S1569-1993(17)30291-6","article-title":"CFHealthHub: complex intervention to support adherence to treatment in adults with cystic fibrosis: external pilot trial","volume":"16 (Suppl 1)","author":"Hind","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD007639.pub3-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s10096-017-3168-4","article-title":"Understanding Pseudomonas status among adults with cystic fibrosis: a real-world comparison of the Leeds criteria against clinicians' decision","volume":"37","author":"Hoo","year":"2018","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD007639.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/thoraxjnl-2017-211453","article-title":"Role of habit in treatment adherence among adults with cystic fibrosis","volume":"74","author":"Hoo","year":"2019","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.chest.2021.06.039","article-title":"Real-world adherence among adults with cystic fibrosis is low: a retrospective analysis of the cfhealthhub digital learning health system","volume":"160","author":"Hoo","year":"2021","journal-title":"Chest"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/S1569-1993(17)30519-2","article-title":"CFHealthHub: using Leeds criteria and clinicians\u2019 decision to determine the pseudomonas status among the 64 adults with cystic fibrosis in the two centre CFHealthHub (CFHH) pilot study","volume":"16 Suppl 1","author":"Hoo","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"issue":"7","key":"10.1002\/14651858.CD007639.pub3-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"e26511","DOI":"10.7759\/cureus.26511","article-title":"Modelling successful self-management in adults with cystic fibrosis: vicarious self-efficacy from videos of 'People Like Me'","volume":"14","author":"Hutchings","year":"2022","journal-title":"Cureus"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0156|cit156","unstructured":"Adherence to treatment in adults with cystic fibrosis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN13076797"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0157|cit157","unstructured":"A randomised controlled trial and parallel process evaluation to determine whether CFHealthHub, an intervention to help CF patients build better treatment habits, offers any benefit over usual care to adults with CF trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN55504164"},{"issue":"Suppl","key":"10.1002\/14651858.CD007639.pub3-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/S1569-1993(16)30505-7","article-title":"Cost-effectiveness of a complex adherence intervention to improve prevention in cystic fibrosis by empowering effective self-management: an exploratory health economic evaluation using UK Registry data","volume":"15 Suppl","author":"Sadler","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"S130","DOI":"10.1016\/S1569-1993(22)00557-4","article-title":"Using CFHealthHub nebuliser duration data to support continuous improvement by optimising inhaled therapy duration to reduce treatment burden within a digital learning health system","volume":"21","author":"Sandler","year":"2022","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40273-017-0500-x","article-title":"An early health economic analysis of the potential cost effectiveness of an adherence intervention to improve outcomes for patients with cystic fibrosis","volume":"35","author":"Tappenden","year":"2017","journal-title":"PharmacoEconomics"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0161|cit161","first-page":"S147","article-title":"Estimating adherence with nebulised therapies: a challenge for people with cystic fibrosis and healthcare professionals","volume":"19 (Suppl 2)","author":"Warnock","year":"2020","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0162|cit162","unstructured":"Wildman M O'Cathain A Development and evaluation of an intervention to support adherence to treatment in adults with Cystic Fibrosis: a randomised controlled trial and parallel process evaluation www.sheffield.ac.uk\/polopoly_fs\/1.688928! \/file\/cfhealthhubrctprotocolv1.213feb17.pdf 2017 1 58"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0163|cit163","first-page":"265","article-title":"Effectiveness of a self-management intervention to support treatment adherence in adults with cystic fibrosis: a randomized controlled trial","volume":"55 (Suppl 2)","author":"Wildman","year":"2020","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0164|cit164","first-page":"92","article-title":"UK National CF healthhub programme: using real-time digital adherence data to support habit formation for self-care","volume":"54 (Suppl 2)","author":"Wildman","year":"2019","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0165|cit165","doi-asserted-by":"crossref","unstructured":"Wildman MJ O'Cathain A Hind D Maguire C Arden MA Hutchings M An intervention to support adherence to inhaled medication in adults with cystic fibrosis: the ACtiF research programme including RCT NIHR Journals Library 2021 34665573","DOI":"10.3310\/pgfar09110"},{"issue":"5","key":"10.1002\/14651858.CD007639.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/thoraxjnl-2021-217594","article-title":"Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial","volume":"77","author":"Wildman","year":"2022","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"S101, Abstract","DOI":"10.1016\/S1569-1993(15)30347-7","article-title":"Safety of nebulised hypertonic saline via Pari eFlow with Pari positive expiratory pressure (PEP) device in circuit for paediatric cystic fibrosis patients","volume":"14 (Suppl 1)","author":"Wilson","year":"2015","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD007639.pub3-BIB0168|cit168","first-page":"939","article-title":"Cystic Fibrosis lung inflammation: early, sustained and severe","volume":"151","author":"Cantin","year":"1995","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0169|cit169","unstructured":"Southern KW Davies G A randomised open label trial to assess change in respiratory function for people with cystic fibrosis (pwCF) established on triple combination therapy (Kaftrio ) after rationalisation of nebulised muco-active therapies (the CF STORM trial) fundingawards.nihr.ac.uk\/award\/NIHR131889 10.1186\/ISRCTN14081521"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0170|cit170","unstructured":"Nebulised\/inhaled medications for people with cystic fibrosis overview Standards of Care and Good Clinical Practice for the Physiotherapy Management of Cystic Fibrosis (Fourth Edition) 2020 211 221"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0171|cit171","unstructured":"Cystic Fibrosis Foundation National Patient Registry. Annual Data Report (Bethesda, Maryland) National Patient Registry 2020"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007639.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1258\/jrsm.2009.s19003","article-title":"Nebulizer therapy in cystic fibrosis: an overview","volume":"102","author":"Collins","year":"2009","journal-title":"Journal of the Royal Society of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD007639.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"606","DOI":"10.4187\/aarc0493","article-title":"Monitoring respiratory disease severity in cystic fibrosis","volume":"54","author":"Davies","year":"2009","journal-title":"Respiratory Care"},{"issue":"5","key":"10.1002\/14651858.CD007639.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Davis PB. Cystic fibrosis since 1938","volume":"173","author":"Davis","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"3","key":"10.1002\/14651858.CD007639.pub3-BIB0175|cit175","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013766.pub2","article-title":"Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis","author":"Dawson","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0176|cit176","doi-asserted-by":"crossref","unstructured":"Cystic Fibrosis in the year 2020: A disease with a new face Acta Paediatrica 109 893 9 https:\/\/doi.org\/10.1111\/apa.15155","DOI":"10.1111\/apa.15155"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007639.pub3-BIB0177|cit177","first-page":"S1","article-title":"The adaptive aerosol delivery (AAD) technology: past, present, and future","volume":"23","author":"Denyer","year":"2010","journal-title":"Journal of Aerosol Medicine and Pumonary Drug Delivery"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0179|cit179","first-page":"228\u201342","article-title":"European Respiratory Society Guidelines on the use of nebulizers","volume":"18","author":"European Respiratory Society Task Force","year":"2001","journal-title":"European Respiratory Journal"},{"issue":"Suppl IV","key":"10.1002\/14651858.CD007639.pub3-BIB0180|cit180","first-page":"71","article-title":"Novel devices for individualised controlled inhalation can optimize aerosol therapy in efficacy, patient care and power of clinical trials","volume":"14","author":"Fischer","year":"2009","journal-title":"European Journal of Respiratory Medicine"},{"issue":"11","key":"10.1002\/14651858.CD007639.pub3-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/thorax.55.11.946","article-title":"Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis","volume":"55","author":"Gee","year":"2000","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD007639.pub3-BIB0182|cit182","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003428.pub2","article-title":"Inhaled bronchodilators for cystic fibrosis","author":"Halfhide","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD007639.pub3-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"295\u2013315","DOI":"10.1016\/j.jcf.2009.04.005","article-title":"Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus","volume":"8","author":"Heijerman","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1023\/A:1022037320039","article-title":"Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients","volume":"12","author":"Henry","year":"2003","journal-title":"Quality of Life Research"},{"issue":"51","key":"10.1002\/14651858.CD007639.pub3-BIB0185|cit185","first-page":"378","article-title":"Key issues in nebulized drug delivery to adults","volume":"7","author":"Higgenbottam","year":"1997","journal-title":"European Respiratory Review"},{"issue":"7414","key":"10.1002\/14651858.CD007639.pub3-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0187|cit187","unstructured":"Higgins JP Altman DG Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0188|cit188","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch VA Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org\/handbook Available from www.training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD007639.pub3-BIB0189|cit189","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1365-2125.199","article-title":"Determination of the relative bioavailability of salbutamol to the lung following inhalation","volume":"34","author":"Hindle","year":"1992","journal-title":"British Jounal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1159\/000056287","article-title":"Treatment of cystic fibrosis in the adult","volume":"67","author":"Hodson","year":"2000","journal-title":"Respiration"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"754","DOI":"10.4187\/002013209790983250","article-title":"New aerosol delivery devices for cystic fibrosis","volume":"54","author":"Kesser","year":"2009","journal-title":"Respiratory Care"},{"issue":"2","key":"10.1002\/14651858.CD007639.pub3-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3","article-title":"Current understanding of the inflammatory process in cystic fibrosis: onset and etiology","volume":"24","author":"Konstan","year":"1997","journal-title":"Pediatric Pulomonolgy"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0193|cit193","unstructured":"Impact of discontinuing chronic therapies in people with cystic fibrosis on highly effective CFTR modulator therapy (SIMPLIFY) clinicaltrials.gov\/ct2\/show\/NCT04378153"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0194|cit194","unstructured":"CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic Medtech innovation briefing Medtech innovation briefing [MIB219] 2020"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0195|cit195","doi-asserted-by":"crossref","unstructured":"Monitoring early stage lung disease in cystic fibrosis Current Opinion in Pulmonary Medicine 26 6 671 6 https:\/\/doi.org\/10.1097\/mcp.0000000000000732","DOI":"10.1097\/MCP.0000000000000732"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD007639.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1136\/thx.52.2008.S31","article-title":"The science of nebulised drug delivery","volume":"52","author":"O'Callaghan","year":"1997","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0198|cit198","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2011"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0199|cit199","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"issue":"3","key":"10.1002\/14651858.CD007639.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1067\/mpd.2001.117288","article-title":"Defining a pulmonary exacerbation in cystic fibrosis","volume":"139","author":"Rosenfeld","year":"2001","journal-title":"Journal of Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD007639.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0022-3476(98)70344-0","article-title":"The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel","volume":"132","author":"Rosenstein","year":"1998","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with Cystic Fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0203|cit203","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). The Cochrane Collaboration, 2022 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0204|cit204","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). The Cochrane Collaboration, 2022 Available from training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD007639.pub3-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR Gene discovery","volume":"11","author":"Scotet","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1002\/14651858.CD007639.pub3-BIB0206|cit206","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013733.pub2","article-title":"Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis","author":"Smith","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007639.pub3-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/thoraxjnl-2021-217594","article-title":"Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial","volume":"77","author":"Wildman","year":"2022","journal-title":"Thorax"},{"issue":"7","key":"10.1002\/14651858.CD007639.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pbio.1000155","article-title":"CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium","volume":"7","author":"Zhang","year":"2009","journal-title":"PLOS Biology"},{"issue":"1","key":"10.1002\/14651858.CD007639.pub3-BIB0209|cit209","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007639","article-title":"Nebuliser devices for drug delivery in cystic fibrosis","author":"Daniels","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD007639.pub3-BIB0210|cit210","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007639.pub2","article-title":"Nebuliser systems for drug delivery in cystic fibrosis","author":"Daniels","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T08:48:47Z","timestamp":1749804527000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007639.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":210,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007639.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]}}}